2023 drug approvals: After a down year, FDA signs off on a bounty of new meds, including 7 from Pfizer

2023 drug approvals: After a down year, FDA signs off on a bounty of new meds, including 7 from Pfizer

Submitted by admin on January 2, 2024 - 10:10am
Source: 
Fierce Pharma
News Tags: 
FDA
drug approvals
Pfizer
COVID-19
Headline: 
2023 drug approvals: After a down year, FDA signs off on a bounty of new meds, including 7 from Pfizer
snippet: 

In 2022, fueled by its powerhouse COVID products, Pfizer became the first company in the history of the biopharma industry to top $100 billion in annual revenue. What would the New York drugmaker do for an encore?

Do Not Allow Advertisers to Use My Personal information